Pemberian Proton Pump Inhibitor Dibandingkan dengan Antagonis Reseptor-H2 pada Anak dengan Penyakit Refluks Gastrointestinal

Pramita G. Dwipoerwantoro, Annisa R Yulman

Sari


Latar belakang. Pada umumnya anak dengan penyakit gastroesofageal refluks (PRGE) diterapi dengan antagonis reseptor H2 (H2RA) atau inhibitor pompa proton (PPI). Keduanya merupakan obat yang tersering diresepkan pada PRGE anak, namun efikasi keduanya masih kontroversi.
Tujuan. Untuk mengevaluasi penggunaan PPI dan H2RA pada anak dengan PRGE melalui telaah sajian kasus berbasis bukti.
Metode. Pencarian literatur secara sistematik menggunakan instrumen pencari PUBMED, Cochrane, dan Google Scholar. Pencarian dibatasi pada literatur berbahasa Inggris, yang dipublikasi selama 15 tahun terakhir, dan usia pasien 0–18 tahun. Studi dianggap memenuhi syarat bila dilakukan secara randomized-controlled trials, mengevaluasi PPI dan/atau H2RA untuk pengobatan GERD anak. Studi yang hanya berupa abstrak, yang hanya mengevaluasi selain non-klinis, dan laporan kasus diekslusi.
Hasil. Studi kohort oleh Ruigomez dkk mencakup 8172 pasien dengan PPI (24 pasien dengan esomeprazole dan 8148 pasien dengan PPI lainnya) dan 7905 dengan H2RA. Karakteristik dasar keduanya serupa, namun anak dengan PPI cenderung lebih tua usianya. Luaran terkait keselamatan sebanyak 92 hanya pada PPI selain esomeprazole. Mattos dkk memperoleh 735 literatur, 23 studi (1598 pasien yang dirandomisasi) yang diikutsertakan dalam review sistematik. Delapan studi membuktikan bahwa PPI dan H2RA cukup efektif mengatasi manifestasi tipikal GERD. Studi lain menunjukkan bahwa omeprazole lebih unggul dibandingkan rantidin dalam pengobatan manifestasi refluks ekstra esofageal.
Kesimpulan. Inhibitor pompa proton (PPI) atau H2RA dapat digunakan untuk pengobatan GERD pada anak. Omeprazol lebih unggul dibandingkan ranitidine pada pengobatan manifestasi refluks ekstra esophageal.


Kata Kunci


inhibitor pompa proton; antagonis reseptor H2; gastroesofageal refluks

Teks Lengkap:

PDF

Referensi


Tighe M, Afzal NA, Bevan A, Hayen A, Munro A, Beattie RM. Pharmacological treatment of children with gastro-oesophageal reflux. Cochrane Database Syst Rev 2014;CD008550.

Vandenplas Y, Hauser B, Devreker T, Mahler T, Degreef E, Wauters GV. Gastro-esophageal reflux in children: Symptoms, diagnosis and treatment. J Pediatr Sci 2011;3:101.

Liu XL, Wong, KKY. Gastroesophageal reflux disease in children. Hong Kong Med J. 2012;18:421-8.

Rosen R, Vandeplas Y, Singendonk M, Cabana M, DiLorenzo C, Gotrand F, dkk. Pediatric gastroesophageal reflux clinical practice guidelines: Joint recommendations of the North American Society for Pediatric Gastoenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2018;66:516–554.

Oxford Centre for Evidence-based Medicine. Levels of Evidence. 2009 March [diakses tanggal 12 Januari 2018]. Didapat dari: http://www.cebm.net/blog/2009/06/11/oxfordcentre-evidence-based-medicine-levels-evidence-march-2009/.

Ruigomez A, Johanssen S, Nagy P, Garcia Rodriguez LA. Utilization and safety of proton-pump inhibitors and histamine-2 receptor antagonists in children and adolescents: an observational cohort study. Curr Med Res Opin 2017;33:2201-09.

Mattos AZ, Marchese GM, Fonseca BB, Kupski C, Machado MB. Antisecretory treatment for pediatric gastroesophageal reflux disease – a systematic review. Arq Gastroenterol 2017;35:271-80.

Gustafsson PM, Kjellman NI, Tibbling L. A trial of ranitidine in asthmatic children and adolescents with or without pathological gastro-oesophageal reflux. Eur J Respir 1992;5:201-6.

Borrelli O, Rea P, Mesquita MB, Ambrosini A, Mancini V, Di Nardo G, dkk. Efficacy of combined administration of an alginate formulation (aviscon) and lansoprazole for children with gastroesophageal reflux disease. Ital J Pediatr 2002;28:304-309.

Stordal K, Johannesdottir GB, Bentsen BS, Knudsen PK, Carlsen KC, Closs O, dkk. Acid suppression does not change respiratory symptoms in children with asthma and gastrooesophageal reflux disease. Arch Dis Child 2005;90:956-60.

Pfefferkorn MD, Croffie JM, Gupta SK, Molleston JP, Eckert GJ, Corkins MR, dkk. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. J Ped Gastroenterol Nutr 2006;42:106-5.

Boccia G, Manguso F, Miele E, Buonavolontà R, Staiano A. Maintenance therapy for erosive esophagitis in children after healing by omeprazole: Is It advisable? Am J Gastroenterol 2007;102:1291-7.

Holbrook JT, Wise RA, Gold BD, Blake K, Brown ED, Castro M, dkk. Randomized clinical trial of lansoprazole for poorly controlled asthma in children: The American Lung Association Asthma Clinical Research Centers. JAMA 2012;307:373-81.

Orenstein SR, Shalaby TM, Devandry SN, Liacouras CA, Czinn SJ, Dice JE, dkk. Famotidine for infant gastrooesophageal reflux: a multi-centre, randomized, placebocontrolled, withdrawal trial. Aliment Pharmacol Ther 2003;17:1097-107.

Moore DJ, Tao BS, Lines DR, Hirte C, Heddle ML, Davidson GP. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr 2003;143:219-23.

Omari TI, Haslam RR, Lundborg P, Davidson GP. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux. J Ped Gastroenterol Nutr 2007;44:41-4.

Orenstein SR, Hassall E, Furmaga-Jablonska W, Atkinson S, Raanan M. Multicenter, double-blind, randomized, placebocontrolled

trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr 2009;154:514-20.

Winter H, Kum-Nji P, Mahomedy SH, Kierkus J, Hinz M, Li H, dkk. Efficacy and safety of pantoprazole delayedrelease granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1–11 months old with symptomatic GERD. J Ped Gastroenterol Nutr 2010;50:609-18.

Winter H, Gunasekaran T, Tolia V, Gottrand F, Barker PN, Illueca M. Esomeprazole for the treatment of GERD in Infants Ages 1–11 Months. J Ped Gastroenterol Nutr 2012;55:14-20.

Davidson G, Wenzl TG, Thomson M, Omari T, Barker P, Lundborg P, dkk. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. J Pediatr 2013;163:692-8.

Hussain S, Kierkus J, Hu P, Hoffman D, Lekich R, Sloan S, dkk. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD. J Pediatr Gastroenterol Nutr 2014;58:226-36.

Loots C, Kritas S, van Wijk M, McCall L, Peeters L, Lewindon P, dkk. Body positioning and medical therapy for infantile gastroesophageal reflux symptoms. J Pediatr Gastroenterol Nutr 2014;59:237-43.

Azizollahi HR, Rafeey M. Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants. Korean J Pediatr 2016;59:226-30.

Cucchiara S, Staiano A, Romaniello G, Capobianco S, Auricchio S. Antacids and cimetidine treatment for gastrooesophageal reflux and peptic oesophagitis. Arch Dis Child 1984;59:842-7.

Argüelles-Martin F, Gonzalez-Fernandez F, Gentles MG. Sucralfate versus cimetidine in the treatment of reflux esophagitis in children. Am J Med 1989;86 Suppl:S73-6.

Cucchiara S, Gobio-Casali L, Balli F, Magazzú G, Staiano A, Astolfi R, dkk. Cimetidine treatment of reflux esophagitis in children: an Italian multicentric study. J Ped Gastroenterol Nutr 1989;8:150-6.

Cucchiara S, Minella R, Iervolino C, Franco MT, Campanozzi A, Franceschi M, dkk. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Arch Dis Child 1993;69:655-9.

Simeone D, Caria MC, Miele E, Staiano A. Treatment of childhood peptic esophagitis: a double-blind placebocontrolled trial of nizatidine. J Ped Gastroenterol Nutr 1997;25:51-5.

Adamko DJ, Majaesic CM, Skappak C, Jones AB. A pilot trial on the treatment of gastroesophageal reflux-related cough in infants. Transl Pediatr 2012;1:23-34.

Ummarino D, Miele E, Masi P, Tramontano A, Staiano A, Vandenplas Y. Impact of antisecretory treatment on respiratory symptoms of gastroesophageal reflux disease in children. Dis Esoph 2012;25:671-7.




DOI: http://dx.doi.org/10.14238/sp20.6.2019.382-91

Refbacks

  • Saat ini tidak ada refbacks.


##submission.copyrightStatement##

##submission.license.cc.by-nc-sa4.footer##

Informasi Editorial:
Badan Penerbit Ikatan Dokter Anak Indonesia
Jl. Salemba I No 5, Jakarta 10430, Indonesia
Phone/Fax: +62-21-3912577
Email: editorial [at] saripediatri.org

Lisensi Creative Commons
Sari Pediatri diterbitkan oleh Badan Penerbit Ikatan Dokter Anak Indonesia
Ciptaan disebarluaskan di bawah Lisensi Creative Commons Atribusi-NonKomersial-BerbagiSerupa 4.0 Internasional.